Ulrike Hemmann

Sanofi (Germany)

Papers

1

Total Citations

74

H-Index

1

About

Dr. Ulrike Hemmann is a leading figure in genetic toxicology, renowned for pioneering high-content, high-throughput approaches to genotoxicity assessment. Her research centers on developing and validating advanced in vitro assays that improve the prediction of chemical carcinogenicity, moving beyond traditional, low-information methods. Her most impactful work, the 2017 study "Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay" (74 citations), describes a revolutionary flow cytometric method that simultaneously measures multiple biomarkers of DNA damage—including p53 activation, γH2AX foci formation, and mitotic disruption—from a single sample of detergent-liberated nuclei. This multiplexed approach dramatically enhances the information yield per experiment, reducing time and cost while increasing mechanistic insight. By demonstrating robust interlaboratory reproducibility, Dr. Hemmann’s work has been instrumental in advancing this assay toward regulatory acceptance and industrial application. Her contributions are vital for modernizing safety assessment, enabling earlier and more accurate identification of genotoxic hazards, and reducing reliance on animal testing.

Research Focus

Key Achievements

1
H-Index
1
Papers
74
Total Citations
74
Avg Citations/Paper
🏆 Most Cited Paper
Interlaboratory evaluation of a multiplexed high information content in vitro genotoxicity assay
74 citations · 2017
📈 Most Prolific Year: 2017 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Sanofi (Germany)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago